Prolongación en el tiempo del efecto del esmolol sobre la regresión del remodelado coronario en ratas espontáneamente hipertensas
Loading...
Download
Official URL
Full text at PDC
Publication date
2022
Defense date
04/10/2021
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citation
Abstract
La hipertensión arterial es responsable del remodelado tanto cardíaco como vascular, dando lugar a eventos adversos cardíacos, tales como arritmias, insuficiencia cardíaca o infarto agudo de miocardio, aumentando la morbimortalidad. Son varios los fármacos antihipertensivos que han demostrado ser capaces de revertir dicho remodelado mejorando así el pronóstico de los pacientes, pero su efecto beneficioso aparece tras meses o incluso años de tratamiento continuado. El esmolol es un fármaco que pertenece al grupo de beta-bloqueantes cardioselectivos con ciertas peculiaridades farmacocinéticas, con efecto cronotrópico negativo y un importante efecto hipotensor ultrarrápido y potente, ampliamente utilizado en la práctica clínica habitual...
Hypertension is responsible for both cardiac and vascular remodeling, leading to adverse cardiac events, such as arrhythmias, heart failure or acute myocardial infarction, increasing morbidity and mortality. There are several antihypertensive drugs that have been shown their ability to reverse this remodeling, thus improving the prognosis of patients, but their beneficial effect appears after months or even years of continuous treatment. Esmolol is a drug that belongs to the group of cardioselective beta-blockers with certain pharmacokinetic peculiarities, with a negative chronotropic effect and an important ultra-rapid and powerful hypotensive effect, widely used in routine clinical practice...
Hypertension is responsible for both cardiac and vascular remodeling, leading to adverse cardiac events, such as arrhythmias, heart failure or acute myocardial infarction, increasing morbidity and mortality. There are several antihypertensive drugs that have been shown their ability to reverse this remodeling, thus improving the prognosis of patients, but their beneficial effect appears after months or even years of continuous treatment. Esmolol is a drug that belongs to the group of cardioselective beta-blockers with certain pharmacokinetic peculiarities, with a negative chronotropic effect and an important ultra-rapid and powerful hypotensive effect, widely used in routine clinical practice...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, leída el 04-10-2021